US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.68

+0.02000.43%

Post-market: 4.680.00000.00%19:38 EDT

Volume:475.31K

Turnover:2.24M

Market Cap:146.44M

PE:-1.13

High:4.81

Open:4.71

Low:4.67

Close:4.66

52wk High:50.40

52wk Low:4.54

Shares:31.29M

Float Shares:18.39M

Volume Ratio:0.74

T/O Rate:2.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.67

PE(LYR):-1.64

Loading ...

Overview Company News Filings

Hemab Therapeutics reports Q2 EPS (80c), consensus (82c)

Tango Therapeutics reports Q2 EPS (37c), consensus (32c)

Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate

Benzinga Earnings

Press Release: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Oruka Therapeutics Price Target Maintained with a $151.00/Share by BTIG

Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target

Analyst Initiates Buy on Damora Therapeutics Citing Strong mCALR Pipeline, Accelerated CLARITY-101 Readouts, and Funding Runway Into 2029

Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?

Simply Wall St.

Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility

MT Newswires Live

DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)

Silence Therapeutics files to sell $150M in ADS’s

Press Release: Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Jade Therapeutics: Buy Rating Reiterated as Strong Cash Position and Pipeline Progress Support Unchanged $42 Price Target

Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LENZ/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.68,"timestamp":1787342400000,"preClose":4.66,"halted":0,"volume":475310,"hourTrading":{"tag":"盘后","latestPrice":4.68,"preClose":4.68,"latestTime":"19:38 EDT","volume":1001,"amount":4691.9184,"timestamp":1787355522649,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00429184549356214,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Market Closed","change":0.02,"latestTime":"08-21 16:00:00 EDT","open":4.71,"high":4.81,"low":4.67,"amount":2238483.85244,"amplitude":0.030043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.66,"preHourTrading":{"tag":"盘前","latestPrice":4.758,"preClose":4.66,"latestTime":"09:26 EDT","volume":1794,"amount":8402.0583504,"timestamp":1787318799174,"change":0.098,"changeRate":0.02103,"amplitude":0.038627},"postHourTrading":{"tag":"盘后","latestPrice":4.68,"preClose":4.68,"latestTime":"19:38 EDT","volume":1001,"amount":4691.9184,"timestamp":1787355522649,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7443221519144751,"impliedVol":0.963,"impliedVolPercentile":0.4104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.7443221519144751,"shares":31289969,"dividePrice":0,"high":4.81,"amplitude":0.030043,"preClose":4.66,"low":4.67,"week52Low":4.535,"pbRate":"0.67","psRate":"6.82","week52High":50.4,"institutionHeld":0,"latestPrice":4.68,"eps":-4.13,"divideRate":0,"volume":475310,"delay":0,"ttmEps":-4.13,"open":4.71,"prevYearClose":16,"prevWeekClose":4.73,"prevMonthClose":5.3,"prevQuarterClose":5.68,"fiveDayClose":4.73,"twentyDayClose":5.48,"sixtyDayClose":7.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-08-21","current":-1.133172,"percent":0.998285,"low":-26.69966,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"high":-1.147074,"avg":-10.725847,"sd":6.107808,"marketCap":146418798},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798}],"updateTime":1787534290253},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658992427","title":"Hemab Therapeutics reports Q2 EPS (80c), consensus (82c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992427","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992427?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:16","pubTimestamp":1786446960,"startTime":"0","endTime":"0","summary":"“This was a very productive quarter for Hemab with continued execution across our pipeline,” said Benny Sorensen, CEO of Hemab. “We had a significa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-reports-q2-eps-80c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-reports-q2-eps-80c-consensus-82c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992232","title":"Tango Therapeutics reports Q2 EPS (37c), consensus (32c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992232?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:15","pubTimestamp":1786446911,"startTime":"0","endTime":"0","summary":"“The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-reports-q2-eps-37c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-reports-q2-eps-37c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994217","title":"Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994217","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994217?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446041,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses of $(0.18) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61102692/autolus-therapeutics-q2-eps-0-15-beats-0-23-estimate-sales-45-689m-beat-34-016m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994107","title":"Press Release: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994107","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994107?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"with Revolution Medicines' RAS inhibitors daraxonrasib or zoldonrasib. in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Data. demonstrated that vopimetostat in combination with daraxonrasib achieved. a 92% objective response rate and 90% six-month progression-free survival. rate in this patient population, with a generally well-tolerated safety. -- Based upon the positive Phase 1/2 data, Tango is working internally and. has initiated dialogue with regulators and its collaborator Revolution. Medicines toward the goal of developing a registrational plan and path. forward for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LU1720051108.HKD","LU1854103824.USD","IE00BZ199S13.USD","BK4512","BK4007","LENZ","LU0124384867.USD","BK4588","LU0724618433.USD","TNGX","BK4141","LU0348723411.USD","LU1983260115.SGD","IE00BD6J9T35.USD","LU1861220033.SGD","LU1854104046.USD","LU1861215975.USD","LU1861219969.SGD","LU1978683503.SGD","LU2360107325.USD","LU1861214812.USD","BK4139","LU2298322129.HKD","BK4605","LU1720051017.SGD","ON","LU2357305700.SGD","BK4585","IE00BFMHRM44.USD","LU1548497426.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899239","title":"Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899239?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, FranceNew cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4119","GCC","COAG","BK4081","EMA","GT","BK4585","BK4539","BK4588","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658991001","title":"Oruka Therapeutics Price Target Maintained with a $151.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658991001","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658991001?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:39","pubTimestamp":1786444740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORKA/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599165","title":"Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599165","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599165?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:15","pubTimestamp":1786443344,"startTime":"0","endTime":"0","summary":"Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on Trevi Therapeutics and keeping the price target at $24.00. Brandon Folkes ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-strong-haduvio-execution-limited-competition-support-buy-rating-and-unchanged-24-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-strong-haduvio-execution-limited-competition-support-buy-rating-and-unchanged-24-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967299","title":"Analyst Initiates Buy on Damora Therapeutics Citing Strong mCALR Pipeline, Accelerated CLARITY-101 Readouts, and Funding Runway Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967299","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658967299?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:45","pubTimestamp":1786430730,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm has maintained their bullish stance on DMRA stock, giving a Buy rating on August 6. Marc Frahm has given his Buy rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-on-damora-therapeutics-citing-strong-mcalr-pipeline-accelerated-clarity-101-readouts-and-funding-runway-into-2029-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-on-damora-therapeutics-citing-strong-mcalr-pipeline-accelerated-clarity-101-readouts-and-funding-runway-into-2029-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999874","title":"Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999874?lang=en_us&edition=fundamental","pubTime":"2026-08-11 13:15","pubTimestamp":1786425335,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics ( HKG:2487 ) is possibly approaching a major achievement in its business, so we would like to shine...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-hkg2487-are-analysts-optimistic-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-hkg2487-are-analysts-optimistic-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK1161","BK4007","LENZ","02487","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658668969","title":"Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2658668969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658668969?lang=en_us&edition=fundamental","pubTime":"2026-08-11 10:23","pubTimestamp":1786415025,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  completed an initial drawdown of around AU$8.3 million under its research and development (R&D) financing facility with Dare Capital Loan Fund, secured against the company's fiscal 2026 R&D tax incentive rebate, according to a Tuesday filing with the Australian bourse.The funds will primarily support the company's continued investment in the pivotal phase two and phase three Healey ALS platform trial, which is now fully recruited and is expected to deliver results in the late second quarter of fiscal 2027, per the filing.The facility provides up to AU$17.5 million in non-dilutive funding, with annual extension options for fiscal 2027 and fiscal 2028 R&D claims, accruing interest at 1.25% per month and repayable upon receipt of the R&D tax incentive refund, the filing added.The company's shares shed nearly 2% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4139","BK4007","BK4539","NUZ.AU","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658510919","title":"DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658510919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658510919?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:40","pubTimestamp":1786394425,"startTime":"0","endTime":"0","summary":"“With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia, we’re eager to continue advancement o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/diamedica-therapeutics-reports-q2-eps-19c-consensus-20c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/diamedica-therapeutics-reports-q2-eps-19c-consensus-20c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951752","title":"Silence Therapeutics files to sell $150M in ADS’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951752?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:35","pubTimestamp":1786394132,"startTime":"0","endTime":"0","summary":"Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers for the proposed offering. Published first on TheFly ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silence-therapeutics-files-to-sell-150m-in-adss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silence-therapeutics-files-to-sell-150m-in-adss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0158827781.USD","LU0098860793.USD","LU1363072403.SGD","LENZ","LU0320765646.SGD","LU0106831901.USD","LU2264538146.SGD","LU0267386448.USD","LU1162221912.USD","LU1244550221.USD","LU2357305700.SGD","LU0528227936.USD","IE00B3S45H60.SGD","IAI","LU2111349929.HKD","BK4516","LU0795875169.SGD","LU0234570918.USD","IE00B775SV38.USD","LU1668664300.SGD","LU1989772923.USD","KBWB","LU0225283273.USD","LU0912757837.SGD","LU2028103732.USD","BK4139","LU1988902786.USD","LU1064131342.USD","LU1720051017.SGD","LU0971096721.USD","BK4504","LU0158827948.USD","IE00BKVL7J92.USD","LU1244550577.SGD","LU1548497426.USD","BK4534","LU1989772840.SGD","LU2089283258.USD","LU1720051108.HKD","LU0882574139.USD","LU2089284900.SGD","BK4581","LU0314104364.USD","LU2347655156.SGD","BK4007","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959553","title":"Press Release: Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959553?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:06","pubTimestamp":1786392360,"startTime":"0","endTime":"0","summary":"tolerability and efficacy of DMR-001 in patients with mutCALR-driven ET. and MF, based on receipt of health authority approval. The Phase 1 dose. escalation portion of the trial is designed to rapidly identify a. recommended dose for expansion cohorts, with a starting dose of 100 mg.  expected to be in the range of anticipated. therapeutic exposure and an adaptive Bayesian design enabling cohort. enrichment. The planned Phase 1b expansion portion of the trial will. further evaluate the safety and efficacy of DMR-001 in additional. populations and settings, including in early-line disease and in. combination with other therapies. Read the press release here.-- Presented DMR-001 preclinical data at the EHA 2026 Congress (Abstract. preclinical studies versus a reference anti-mutCALR antibody, DMR-001. showed up to 30-fold higher binding affinity for mutCALR, 26-fold greater. inhibition of cellular proliferation in Type 2 mutCALR, an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DMRA","XELA","BK4134","ET","USAI","UMI","BK4561","BK4590","BK4539","EIPI","EMLP","AMLP","TPZ","BK4526","BK4563","BK4581","TNGY","EIPX","BK4585","AMZA","MDST","BK4139","BK4144","BK4113","BK4588","ENFR","BK4106","BK4007","BK4226","MLPA","MF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959548","title":"Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959548?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"of the third quarter of 2026, including GLP toxicity. The Company remains. on track to submit an IND application in the fourth quarter of 2026 for. the global clinical program, and subject to regulatory clearance,-- Two Metagenomi scientific posters received Top Poster Awards at the 2026. International Society on Thrombosis and Haemostasias  Congress in. Paris, France, including one highlighting extensive non-human primate. preclinical data supporting MGX-001.MGX-001 - Large Gene Integration System for Protein Replacement via Gene Insertion-- The Company continues to evaluate disease indications which have the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","IND","MGX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658955317","title":"Jade Therapeutics: Buy Rating Reiterated as Strong Cash Position and Pipeline Progress Support Unchanged $42 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2658955317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658955317?lang=en_us&edition=fundamental","pubTime":"2026-08-11 02:15","pubTimestamp":1786385723,"startTime":"0","endTime":"0","summary":"In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Jade Biosciences, with a price target of $42.00. Rami Kat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/jade-therapeutics-buy-rating-reiterated-as-strong-cash-position-and-pipeline-progress-support-unchanged-42-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/jade-therapeutics-buy-rating-reiterated-as-strong-cash-position-and-pipeline-progress-support-unchanged-42-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658649958","title":"Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2658649958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658649958?lang=en_us&edition=fundamental","pubTime":"2026-08-11 00:25","pubTimestamp":1786379158,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Aprea Therapeutics, retaining the price target of $1.20. Joseph Pantginis ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aprea-therapeutics-buy-rating-reiterated-as-apr-1051-clinical-momentum-builds-1-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aprea-therapeutics-buy-rating-reiterated-as-apr-1051-clinical-momentum-builds-1-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937296","title":"Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658937296?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:10","pubTimestamp":1786374608,"startTime":"0","endTime":"0","summary":"11:09 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause Published first on TheFly – the ultimate source f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/obsidian-therapeutics-inc-common-stock-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/obsidian-therapeutics-inc-common-stock-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSEE","QQQP","BK4539","JULD","OBX","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658932066","title":"Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film","url":"https://stock-news.laohu8.com/highlight/detail?id=2658932066","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658932066?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:43","pubTimestamp":1786372980,"startTime":"0","endTime":"0","summary":"Shares of Aquestive Therapeutics were higher after the pharmaceutical company reported positive topline results for its study of Anaphylm sublingual film, which treats allergic reactions.The stock was up 13% at $4.46 in recent trading, but fell 31% since the start of the year.The study was conducted in support of the company's submission of its new drug application to the U.S. Food and Drug Administration for the treatment of Type 1 allergic reactions, including anaphylaxis.Chief Executive Daniel Barber said if anaphylm is approved it has the potential to be the first and only non-invasive, orally delivered epinephrine product for patients at risk of life-threatening allergic reactions.The company said the new study showed that there was significant improvement across each deficiency identified by the FDA, including difficulties with opening the pouch.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007","AQST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893427","title":"Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893427","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893427?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:58","pubTimestamp":1786370315,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said Monday that it has launched SPY772, a program that combines SPY072, a long-acting anti-TL1A antibody, and SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development.The program is designed to treat patients with Hidradenitis Suppurativa, which is a skin condition that causes painful lumps deep within the skin, Spyre said.The clinical-stage company said it has initiated a mid-stage proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F to treat Hidradenitis Suppurativa. The study is expected to enroll 150 adults. Topline results are expected late next year or early 2028.Price: 104.61, Change: -0.30, Percent Change: -0.29","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LFSC","LENZ","BK4539","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993909","title":"Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993909","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993909?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366860,"startTime":"0","endTime":"0","summary":"Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceAppointment further streng","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IBB","SYNB","BK4205","BK4007","BK4233","ERNA","BBP","BK4539","XBI","BK4585","BK4588","IND","BK4139","LENZ","RFL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":11,"totalSize":233,"code":"91000000","status":"200"}]}}